Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Marth, C; Windbichler, GH; Hausmaninger, H; Petru, E; Estermann, K; Pelzer, A; Mueller-Holzner, E.
Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study.
Int J Gynecol Cancer. 2006; 16(4): 1522-1528. Doi: 10.1111/j.1525-1438.2006.00622.x
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz
Petru Edgar
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
We have previously shown that interferon-gamma 1b (IFN-gamma) in combination with cyclophosphamide and cisplatin significantly prolongs progression-free survival in ovarian cancer. In this phase I/II study, we examined if administration of IFN-gamma is also safe in combination with the current standard treatment, paclitaxel and carboplatin. Thirty-four patients with newly diagnosed advanced epithelial ovarian cancer, FIGO stage III/IV, were treated for six to nine cycles with paclitaxel (175 mg/m(2)) and carboplatin (area under the curve [AUC] 5) every 3 weeks. IFN-gamma was administered in an escalating dose from 6 days/cycle with 0.025 mg sc up to 9 days/cycle with 0.1 mg sc. As expected, administration of IFN-gamma was associated with flu-like symptoms. Grade 3/4 neutropenia was observed in 74% (25 out of 34) of patients. Other side effects, in particular peripheral neuropathies, were within the previously observed ranges for the paclitaxel plus carboplatin combination. Overall response rate (complete or partial response) in patients who received either six or nine doses (0.1 mg) of IFN-gamma/cycle (n = 28) was 71%. IFN-gamma is safe in combination with carboplatin and paclitaxel for first-line treatment of patients with advanced ovarian cancer. This combination should be further evaluated as an immunotherapeutic treatment option for ovarian cancer.
Find related publications in this database (using NLM MeSH Indexing)
Adenocarcinoma, Mucinous - drug therapy
Adult - drug therapy
Aged - drug therapy
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration and dosage
Cystadenocarcinoma, Serous - drug therapy
Disease-Free Survival - drug therapy
Endometrial Neoplasms - drug therapy
Female - drug therapy
Humans - drug therapy
Interferon Type II - administration and dosage
Middle Aged - administration and dosage
Neoplasm Staging - administration and dosage
Ovarian Neoplasms - drug therapy
Paclitaxel - administration and dosage
Survival Rate - administration and dosage
Treatment Outcome - administration and dosage

Find related publications in this database (Keywords)
carboplatin
interferon-gamma
ovarian cancer
paclitaxel
© Med Uni GrazImprint